(1) Pretomanid FGK, European Medicines Agency, 26 March 2020. Disponible en: https://www.ema.europa.eu/en/medicines/human/summaries-opinion/pretomanid-fgk [https://c212.net/c/link/?t=0&l=es&o=2872101-1&h=469118128&u=https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fmedicines%2Fhuman%2Fsummaries-opinion%2Fpretomanid-fgk&a=https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fmedicines%2Fhuman%2Fsummaries-opinion%2Fpretomanid-fgk] (2) Conradie F, et al. Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis. N Eng J Med 2020;382:893-902.(3 )TB Alliance. Data on File. Pretomanid and BPaL Regimen for Treatment of Highly Resistant Tuberculosis.(4) TB Alliance and Mylan Announce Global Collaboration to Commercialize Investigational Drug Pretomanid as Part of Two Regimens to Treat Tuberculosis. April 2019. https://www.tballiance.org/news/tb-alliance-and-mylan-announce-global-collaboration-commercialize-investigational-drug [https://c212.net/c/link/?t=0&l=es&o=2872101-1&h=2758574478&u=https%3A%2F%2Fwww.tballiance.org%2Fnews%2Ftb-alliance-and-mylan-announce-global-collaboration-commercialize-investigational-drug&a=https%3A%2F%2Fwww.tballiance.org%2Fnews%2Ftb-alliance-and-mylan-announce-global-collaboration-commercialize-investigational-drug] (5) The Review on Antimicrobial Resistance. Tackling Drug- Resistant Infections Globally. May 2016. (6 )World Health Organization (WHO). Global TB Report 2019. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1 [https://c212.net/c/link/?t=0&l=es&o=2872101-1&h=278633716&u=https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F329368%2F9789241565714-eng.pdf%3Fua%3D1&a=https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F329368%2F9789241565714-eng.pdf%3Fua%3D1]

Foto -- https://mma.prnewswire.com/media/1222745/TB_Alliance_European_Commission_Authorisation_photo.jpg [https://c212.net/c/link/?t=0&l=es&o=2872101-1&h=750586040&u=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1222745%2FTB_Alliance_European_Commission_Authorisation_photo.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1222745%2FTB_Alliance_European_Commission_Authorisation_photo.jpg]

CONTACTO: Para cualquier solicitud de medios, por favor comunicarse con:Thomas Lynch, Thomas.Lynch@tballiance.org, +1 917 648 0671;Anne-MarieSchryer-Roy, aschryer-roy@burness.com, +254 727 305 525